Please login to the form below
larotrectinib
This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.
Immuno-oncology, personalised medicine continues to drive pharma sector
A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was
Latest news
-
NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
In a blow to Bayer, NICE also said in the statement that Roche’s Vitrakvi (larotrectinib) rival Rozlytrek (entrectinib) could instead become the first histology independent treatment to be made available ... In its draft guidance, the NICE committee
-
Lilly expands dermatology portfolio with $1.1bn Dermira deal
From that deal, Lilly gained TRK inhibitor Vikrakvi (larotrectinib), a targeted cancer drug for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours with a neurotrophic
-
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
Will likely face competition soon from rival Rozlytrek. Bayer’s Vitrakvi (larotrectinib) has become the first tumour-agnostic drug in Europe to be approved for the treatment of cancer.
-
Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
The company has just picked up a new approval for targeted cancer drug Rozlytrek(entrectinib), a rival to Bayer’s Vitrakvi (larotrectinib), and for anti-CD79b antibody drug conjugate Polivy (polatuzumab
-
Roche undercuts price of Bayer cancer drug after winning FDA approval
Both drugs highly effective in small subset of patients. Roche has won US Food and Drug Administration (FDA) approval for its rival to Bayer’s oncology drug Vitrakvi (larotrectinib).
More from news
Approximately 2 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Vitrakvi(larotrectinib) gained FDA approval in late November to treat any solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which causes the production of TRK, a family ... In Europe, a marketing application for
-
Cancer immunotherapy: What's on the horizon?
also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
